Hypercholesterolemia - Is lipid-lowering worthwhile for older patients

被引:0
|
作者
Deedwania, PC [1 ]
机构
[1] VA Cent Calif Hlth Care Syst, Fresno, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
来源
GERIATRICS-US | 2000年 / 55卷 / 05期
关键词
D O I
暂无
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Despite some indications to the contrary, evidence continues to accumulate that controlling cholesterol levels with drug therapy in older persons is a worthwhile goal. Older persons with hypercholesterolemia have an elevated risk of coronary heart disease morbidity and mortality, and this risk increases as they age. Recent clinical trials have suggested that older persons benefit from lipid-lowering therapy as much as younger patients do. Therefore, intervention appears to be justified-as is greater vigilance in identifying untreated patients.
引用
收藏
页码:22 / +
页数:8
相关论文
共 50 条
  • [41] Lipid-lowering effect of 2 dosages of a soy protein supplement in hypercholesterolemia
    Hoie, LH
    Graubaum, HJ
    Harde, A
    Gruenwald, J
    Wernecke, KD
    ADVANCES IN THERAPY, 2005, 22 (02) : 175 - 186
  • [42] Lomitapide and Mipomersen Novel Lipid-Lowering Agents for the Management of Familial Hypercholesterolemia
    Dixon, Dave L.
    Sisson, Evan M.
    Butler, Michael
    Higbea, Ashley
    Muoio, Brendan
    Turner, Brandy
    JOURNAL OF CARDIOVASCULAR NURSING, 2014, 29 (05) : E7 - E12
  • [43] Plant sterol supplementation on top of lipid-lowering therapies in familial hypercholesterolemia
    Machado, Valeria A.
    Fonseca, Francisco A.
    Fonseca, Henrique A.
    Malina, Daniela T.
    Fonzar, Waleria T.
    Barbosa, Silvio A.
    Santana, Jose M.
    Izar, Maria C.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 : 570 - 572
  • [44] The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
    Butt, Waleed Z.
    Yee, Jennifer K.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (05) : 379 - 389
  • [45] Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review
    Masson, Walter
    Corral, Pablo
    Barbagelata, Leandro
    Lavalle-Cobo, Augusto
    Nogueira, Juan P.
    Siniawski, Daniel
    Ray, Kausik K.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 562 - 573
  • [47] Lipid lowering 'not always worthwhile'
    Eckert, RM
    GERIATRICS, 2000, 55 (07) : 15 - 15
  • [48] Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome
    Nakao, Sho
    Ishihara, Takayuki
    Tsujimura, Takuya
    Iida, Osamu
    Hata, Yosuke
    Toyoshima, Taku
    Higashino, Naoko
    Mano, Toshiaki
    JOURNAL OF CARDIOLOGY, 2022, 79 (03) : 391 - 399
  • [49] Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
    Yamashita, Shizuya
    Masuda, Daisaku
    Harada-Shiba, Mariko
    Arai, Hidenori
    Bujo, Hideaki
    Ishibashi, Shun
    Daida, Hiroyuki
    Koga, Nobuhiko
    Oikawa, Shinichi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (05) : 608 - 638
  • [50] Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia
    Lin, Dai-Yi
    Tsai, Chia-Ling
    Chang, Ya-Hui
    Liang, Chih-Hung
    Chuang, Jen-Yu
    Chen, Yi-Han
    Yeh, Hung-, I
    Lin, Chao-Feng
    ACTA CARDIOLOGICA SINICA, 2022, 38 (06) : 778 - 783